Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human LILRB1/CD85j/ILT2 Fluorescein-conjugated Antibody, R&D Systems™
Mouse Monoclonal Antibody has been used in 2 publications
Supplier: R&D Systems FAB20171F025
This item is not returnable.
View return policy
Description
ILT2/CD85j/LILRB1 Monoclonal specifically detects ILT2/CD85j/LILRB1 in Human samples. It is validated for Flow Cytometry.Specifications
ILT2/CD85j/LILRB1 | |
Monoclonal | |
Fluorescein | |
Supplied in a saline solution containing BSA and Sodium Azide. with Sodium Azide | |
CD85 antigen-like family member J, CD85J, CD85j antigen, Ig-like transcript 2, ILT2, ILT-2, ILT2FLJ37515, Immunoglobulin-like transcript 2, leukocyte Ig-like receptor-1, Leukocyte immunoglobulin-like receptor 1, leukocyte immunoglobulin-like receptor subfamily B member 1, leukocyte immunoglobulin-like receptor subfamily B member 1 soluble isoform, leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), LIR1, LIR1LIR-1MIR-7CD85MIR7CD85 antigen, member 1, MIR7, Monocyte/macrophage immunoglobulin-like receptor 7 | |
Mouse | |
Protein A or G purified from hybridoma culture supernatant | |
RUO | |
10859 | |
Human | |
Purified |
Flow Cytometry | |
292305 | |
Flow Cytometry 10 uL/10^6 cells | |
Q8NHL6 | |
LILRB1 | |
Mouse myeloma cell line NS0-derived recombinant human ILT2/CD85j Gly24-His458 Accession # Q8NHL6 | |
25 Tests | |
Primary | |
Detects human ILT2/CD85j in Western blots. In Western blots, no cross-reactivity with recombinant human (rh) ILT4, rhILT5, rhLIR6 or rhLIR8 is observed. | |
Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 degreesC as supplied. | |
IgG1 |
Provide Content Correction
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?
Provide Content Correction